Progenics Pharmaceuticals Inc. (PGNX): Earnings News

PGNX – Beats EPS loss estimates by $0.19 and beats on revenues.


Key Facts Surrounding This News Item


  • PGNX had a POWR Rating of C (Neutral) coming into today.
  • PGNX was 7.91% above its 10-Day Moving Average coming into today.
  • PGNX was 16.88% above its 20-Day Moving Average coming into today.
  • PGNX was 17.48% above its 50-Day Moving Average coming into today.
  • PGNX was 20.09% above its 100-Day Moving Average coming into today.
  • PGNX was 14.53% above its 200-Day Moving Average coming into today.
  • PGNX had returned +21.34% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Progenics Pharmaceuticals Inc. (PGNX)


Progenics Pharmaceuticals is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. The company was founded in 1986 and is based in Tarrytown, New York. View our full PGNX ticker page with ratings, news, and more.

PGNX at a Glance

PGNX Current POWR Rating™
Overall POWR Rating™
PGNX Current Price $4.69 5.82%
More PGNX Ratings, Data, and News

PGNX Price Reaction

The day of this event (Mar. 8, 2018)
PGNX Closing Price$8.32 15.24%
PGNX Volume5,444,900
409.62% from avg
Leading up to this event
PGNX 1-mo return34.95%
After this event
PGNX 1-day return10.86%
PGNX 3-day return12.80%
PGNX 5-day return13.01%

PGNX Price Chart


The Top Stocks For 2019

More Progenics Pharmaceuticals Inc. (PGNX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All PGNX News
Page generated in 0.9207 seconds.